What is Pacific Edge?
Pacific Edge stands as a unique entity in the global market, offering a comprehensive suite of molecular diagnostic tests specifically designed for bladder cancer. These tests cater to various needs across the diagnostic and treatment continuum, from the initial investigation of hematuria to the ongoing management of patients diagnosed with the disease and requiring follow-up evaluations for recurrence. The company is strategically positioning its Cxbladder technology, recognized for its high accuracy, non-invasive nature, and cost-effectiveness, as the preferred diagnostic tool for clinicians and urologists. There is a discernible increase in demand and adoption from both private and public healthcare providers, indicating a growing acceptance and integration of their innovative solutions into standard clinical practice.
How much funding has Pacific Edge raised?
Pacific Edge has raised a total of $36.7M across 2 funding rounds:
Stock/Share Issuance
$16M
Other Financing Round
$20.7M
Stock/Share Issuance (2025): $16M, investors not publicly disclosed
Other Financing Round (2025): $20.7M, investors not publicly disclosed
What's next for Pacific Edge?
The substantial enterprise-level funding, highlighted by the recent strategic investment of $20.7M, positions Pacific Edge for accelerated growth and market penetration. This capital infusion is expected to fuel further development of its diagnostic platforms, expand its commercial reach, and potentially explore new applications within oncology. The company's focus on non-invasive, accurate, and cost-effective solutions aligns with global healthcare trends emphasizing value-based care and improved patient outcomes. Future strategic initiatives will likely involve strengthening partnerships with healthcare systems, enhancing clinical validation, and scaling operations to meet the increasing demand for its specialized diagnostic tools.
See full Pacific Edge company page
